All In Biotech

Drug Trial Radar · NCT02988089

Antimicrobial Susceptibility Testing Guided Antibiotic Selection Strategies in Salvage Helicobacter Pylori Treatment

Efficacy of Two Antimicrobial Susceptibility Testing Guided Antibiotic Selection Strategies in Salvage Helicobacter Pylori Treatment

Last checked: Nov 19, 2026Latest source record: Apr 25, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 480 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

480

Planned (sponsor's estimate)

Start

Apr 20, 2017

Primary completion

Sep 2017

Study completion Sep 2017

Sponsor

Lead sponsor
Shandong UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Shandong Provincial Hospital; General Hospital of Jinan Military Region; Binzhou People's Hospital; Liaocheng People's Hospital
First posted
Dec 9, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Helicobacter pylori (H. pylori), which infects about 50% of the global population, has been recognized as a main risk factor of multiple gastric pathologies, especially non-cardiac gastric cancer. Strongly evidence supports that H. pylori eradication is an effective approach to reduce the incidence of those pathologies.

Conditions

  • Helicobacter Pylori Infection
  • Antimicrobial Susceptibility Testing

Interventions

  • Clarithromycin susceptibility dependant strategyDrug

    Patients in this group will receive a 14-day bismuth-based quadruple regimen to eradicate H. pylori. Antimicrobial susceptibility testing (AST) will be used to test the susceptibility of clarithromycin. If clarithromycin is susceptible, amoxicillin 1 g b.i.d and clarithromycin 500 mg b.i.d will be chosen; If clarithromycin is resistant, amoxicillin 1 g bid and furazolidone 100 mg b.i.d will be chosen.

  • 2 susceptible antibiotics (amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline )Drug

    Patients in this group will receive a a 14-day bismuth-based quadruple regimen to eradicate H. pylori. The regimen is consist of a PPI, Colloidal Bismuth Pectin and 2 susceptible antibiotics which are determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline will be evaluated.

  • proton pump inhibitor (PPI) and Colloidal Bismuth PectinDrug

    all patients need these two drugs.

  • amoxicillin and clarithromycin or amoxicillin and furazolidoneDrug

    patients in the 6 antibiotics dependant group will use these intervention.

  • amoxicillin and furazolidone or amoxicillin and tetracyclineDrug

    salvage therapy for negative culture when the results of culture are negative

  • amoxicillin and furazolidone or amoxicillin and Tinidazole or amoxicillin and LevofloxacinDrug

    salvage therapy for failed eradication if failed with AST guided eradication therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Eradication rates in 2 groupsTime frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Department of Gastroenterology, Qilu Hospital, Shandong University

    Ji'nan, Shandong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.